5 Analysts Assess IQVIA Hldgs: What You Need To Know

In the last three months, 5 analysts have published ratings on IQVIA Hldgs IQV, offering a diverse range of perspectives from bullish to bearish.

The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $262.4, a high estimate of $292.00, and a low estimate of $245.00. Experiencing a 4.67% decline, the current average is now lower than the previous average price target of $275.25.

Interpreting Analyst Ratings: A Closer Look

A clear picture of IQVIA Hldgs's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to IQVIA Hldgs. This information provides a snapshot of how analysts perceive the current state of the company.
• Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of IQVIA Hldgs compared to the broader market.
• Price Targets: Analysts predict movements in price targets, offering estimates for IQVIA Hldgs's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.

Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of IQVIA Hldgs's market position. Stay informed and make well-informed decisions with our Ratings Table.

Stay up to date on IQVIA Hldgs analyst ratings.

Unveiling the Story Behind IQVIA Hldgs

IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.

IQVIA Hldgs: Financial Performance Dissected

Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.

Positive Revenue Trend: Examining IQVIA Hldgs's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 2.33% as of 31 March, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.

Net Margin: IQVIA Hldgs's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 7.71% net margin, the company effectively manages costs and achieves strong profitability.

Return on Equity (ROE): IQVIA Hldgs's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 4.62%, the company showcases efficient use of equity capital and strong financial health.

Return on Assets (ROA): IQVIA Hldgs's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.08% ROA, the company effectively utilizes its assets for optimal returns.

Debt Management: IQVIA Hldgs's debt-to-equity ratio stands notably higher than the industry average, reaching 2.17. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.

How Are Analyst Ratings Determined?

Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.

In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.

This article was generated by Benzinga's automated content engine and reviewed by an editor.